Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2 - Overexpressing locally advanced breast cancers

Journal of Clinical Oncology

Volumn 29, Issue 2, 2011, Pages 166-173

  Dave, Bhuvanesh ^a   Migliaccio, Ilenia ^a   Gutierrez, M Carolina ^a   Wu, Meng Fen ^a   Chamness, Gary C ^a   Wong, Helen ^a   Narasanna, Archana ^a   Chakrabarty, Anindita ^a   Hilsenbeck, Susan G ^a   Huang, Jian ^a   Rimawi, Mothaffar ^a   Schiff, Rachel ^a   Arteaga, Carlos ^a   Osborne, C Kent ^a   Chang, Jenny C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENOMIC DNA; KI 67 ANTIGEN; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TRASTUZUMAB;

ADVANCED CANCER; APOPTOSIS; ARTICLE; BREAST CANCER; DRUG EFFECT; ENZYME ACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; IN VITRO STUDY; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; CLINICAL TRIALS, PHASE II AS TOPIC; ENZYME ACTIVATION; FEMALE; HUMANS; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; PHOSPHATIDYLINOSITOL 3-KINASES; PTEN PHOSPHOHYDROLASE; QUINAZOLINES; RECEPTOR, ERBB-2; RNA, SMALL INTERFERING; TAXOIDS; TRANSFECTION;

EID: 79951997890     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.7814     Document Type: Article

References (26)

1. Riese DJ 2nd, Stern DF: Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20:41-48, 1998
2. Amundadottir LT, Leder P: Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene 16:737-746, 1998 (Pubitemid 28076084)
3. Okano J, Gaslightwala I, Birnbaum MJ, et al: Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. J Biol Chem 275:30934-30942, 2000
4. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005 (Pubitemid 41464706)
5. Rusnak DW, Affleck K, Cockerill SG, et al: The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer. Cancer Res 61:7196-7203, 2001 (Pubitemid 32946515)
6. DeSimone PA, Bence AK, Anderson EB, et al: A phase I study to investigate the safety, tolerability, and pharmacokinetics of single oral escalating doses of GW572016 in healthy volunteers. Proc Am Soc Clin Oncol 21:34a, 2002 (abstr 375)
7. Blackwell K, Kaplan E, Franco S, et al: A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. J Clin Oncol 22:196, 2004 (suppl 14S; abstr 3006)
8. Dees EC, Burris H, Hurwitz H, et al: Clinical summary of 67 heavily pre-treated patients with metastatic carcinomas treated with GW572016 in a phase Ib study. J Clin Oncol 22:241, 2004 (suppl 14S; abstr 3188)
9. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006 (Pubitemid 46021510)
10. Johnston S, Pippen J Jr, Pivot X, et al: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538-5546, 2009
11. Cho HS, Mason K, Ramyar KX, et al: Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:756-760, 2003 (Pubitemid 36227628)
12. Smith KL, Robbins PD, Dawkins HJS, et al: Detection of c-erbB-2 amplification in breast cancer by in situ hybridization. Breast 2:234-238, 1993 (Pubitemid 24003493)
13. Nahta R, Yuan LX, Zhang B, et al: Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65:11118-11128, 2005 (Pubitemid 41713383)
14. Berns K, Horlings HM, Hennessy BT, et al: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395-402, 2007 (Pubitemid 47539306)
15. Xia W, Mullin RJ, Keith BR, et al: Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21: 6255-6263, 2002
16. Mohsin SK, Weiss HL, Gutierrez MC, et al: Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 23:2460-2468, 2005 (Pubitemid 47050836)
17. Kuerer HM, Newman LA, Buzdar AU, et al: Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 176:502-509, 1998 (Pubitemid 29056639)
18. Li X, Lewis MT, Huang J, et al: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100:672-679, 2008
19. Allred DC, Harvey JM, Berardo M, et al: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168, 1998 (Pubitemid 28144151)
20. Clopper CJ, Pearson ES: The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26:404-413, 1934
21. Nagata Y, Lan KH, Zhou X, et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117-127, 2004 (Pubitemid 39485684)
22. Bacus SS, Stancovski I, Huberman E, et al: Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. Cancer Res 52:2580-2589, 1992
23. Peng D, Fan Z, Lu Y, et al: Anti-epidermal growth factor receptor monoclonal antibody 225 upregulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 56:3666-3669, 1996 (Pubitemid 26272010)
24. Ben-Bassat H, Rosenbaum-Mitrani S, Hartzstark Z, et al: Inhibitors of epidermal growth factor receptor kinase and of cyclin-dependent kinase 2 activation induce growth arrest, differentiation, and apoptosis of human papilloma virus 16-immortalized human keratinocytes. Cancer Res 57: 3741-3750, 1997 (Pubitemid 27381218)
25. Xia W, Husain I, Liu L, et al: Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res 67:1170-1175, 2007
26. Eichhorn PJ, Gili M, Scaltriti M, et al: Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 68:9221-9230, 2008